Investigating ioflupane I¹²³ injection and single photon emission tomography as an imaging biomarker for long-term sequelae following mild traumatic brain injury

References

• TBI data and statistics. [accessed 2016 Oct 28].http://www.cdc.gov/TraumaticBrainInjury/data/index.html#.
   Google Scholar
• Gardner RC, Yaffe K. Epidemiology of mild traumatic brain injury and neurodegenerative disease. Mol Cell Neurosci. 2015;66:75–80. doi:10.1016/j.mcn.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson’s disease risk in twins. Ann Neurol. 2006;60:65–72. doi:10.1002/ana.v60:1.
   PubMed Web of Science ®Google Scholar
• Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study. Bmj. 2008;337:a2494. doi:10.1136/bmj.a2494.
   PubMed Web of Science ®Google Scholar
• Crane PK, Gibbons LE, Dams-O’Connor K, Trittschuh E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennett DA, Leurgans S, et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 2016;73:1062–69. doi:10.1001/jamaneurol.2016.1948.
   PubMed Web of Science ®Google Scholar
• Marras C, Hincapié CA, Kristman VL, Cancelliere C, Soklaridis S, Li A, Borg J, Af Geijerstam JL, Cassidy JD. Systematic review of the risk of Parkinson’s disease after mild traumatic brain injury: results of the international collaboration on mild traumatic brain injury prognosis. Arch Phys Med Rehabil. 2014;95:S238–44. doi:10.1016/j.apmr.2013.08.298.
   PubMedGoogle Scholar
• Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology. 2003;60:1610–15. doi:10.1212/01.WNL.0000068008.78394.2C.
   PubMed Web of Science ®Google Scholar
• Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord. 2013;28:1222–29. doi:10.1002/mds.v28.9.
   PubMedGoogle Scholar
• Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol. 1999;58:1263–68. doi:10.1097/00005072-199912000-00007.
   PubMed Web of Science ®Google Scholar
• Su E, Bell MJ, Wisniewski SR, Adelson PD, Janesko-Feldman KL, Salonia R, Clark RS, Kochanek PM, Kagan VE, Bayır H. α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci. 2010;32:385–95.
   PubMed Web of Science ®Google Scholar
• Uryu K, Giasson BI, Longhi L, Martinez D, Murray I, Conte V, Nakamura M, Saatman K, Talbot K, Horiguchi T, et al. Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol. 2003;184:214–24. doi:10.1016/S0014-4886(03)00245-0.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40. doi:10.1038/42166.
   PubMed Web of Science ®Google Scholar
• Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743–50. doi:10.1002/ana.21380.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–47. doi:10.1126/science.276.5321.2045.
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841. doi:10.1126/science.1090278.
   PubMed Web of Science ®Google Scholar
• Maraganore DM, De Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, et al. Genetic Epidemiology of Parkinson’s Disease (GEO-PD) consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. Jama. 2006;296:661–70. doi:10.1001/jama.296.6.661.
   PubMed Web of Science ®Google Scholar
• Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, et al. Head injury, α-synuclein Rep1, and Parkinson’s disease. Ann Neurol. 2012;71:40–48. doi:10.1002/ana.22499.
   PubMed Web of Science ®Google Scholar
• Benamer TS, Patterson J, Grosset DG, Booij J, De Bruin K, Van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10. doi:10.1002/1531-8257(200005)15:31.0.CO;2-5.
   PubMed Web of Science ®Google Scholar
• Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500–08. doi:10.1002/mds.22108.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Fine MJ, Grachev ID, Jarecke CR, Johnson MK, Kuo PH, Schaecher KL, Oberdorf JA, Rezak M, Riley DE, et al. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™). Am J Manag Care. 2014;20:S97–109.
   PubMed Web of Science ®Google Scholar
• Maraganore DM, O’Connor MK, Bower JH, Kuntz KM, McDonnell SK, Schaid DJ, Rocca WA. Detection of preclinical Parkinson disease in at-risk family members with use of [123I]beta-CIT and SPECT: an exploratory study. Mayo Clin Proc. 1999;74:681–85. doi:10.4065/74.7.681.
   PubMed Web of Science ®Google Scholar
• Newberg AB, Serruya M, Gepty A, Intenzo C, Lewis T, Amen D, Russell DS, Wintering N. Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury. PLoS One. 2014;9:e87009. doi:10.1371/journal.pone.0087009.
   PubMed Web of Science ®Google Scholar
• Rutherford WH, Merrett JD, McDonald JR. Symptoms at one year following concussion from minor head injuries. Injury. 1979;10:225–30. doi:10.1016/0020-1383(79)90015-9.
   PubMed Web of Science ®Google Scholar
• Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, Wenning GK. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med. 2000;27:1410–14. doi:10.1007/s002590000308.
   PubMedGoogle Scholar
• Fahn S, Elton R. Members of the UPDRS development committee. The unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson’s disease. New Jersey: Macmillan; 1987. p. 153–63, 293–304.
   Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42. doi:10.1212/WNL.17.5.427.
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52:1214–20. doi:10.1212/WNL.52.6.1214.
   PubMed Web of Science ®Google Scholar
• GE Healthcare. DaTQUANT™ Software for Your PC. [accessed 2017 Aug 22]. http://www3.gehealthcare.com/en/products/categories/nuclear_imaging_agents/datquant.
   Google Scholar
• Scopaz KA, Hatzenbuehler JR. Risk modifiers for concussion and prolonged recovery. Sports Health. 2013;5:537–41. doi:10.1177/1941738112473059.
   PubMedGoogle Scholar
• Whelan-Goodinson R, Ponsford J, Johnston L, Grant F. Psychiatric disorders following traumatic brain injury: their nature and frequency. J Head Trauma Rehabil. 2009;24:324–32. doi:10.1097/HTR.0b013e3181a712aa.
   PubMed Web of Science ®Google Scholar
• Cole WR, Bailie JM. Neurocognitive and psychiatric symptoms following mild traumatic brain injury. In: Laskowitz D, Grant G, editors. Translational research in traumatic brain injury. Boca Raton (FL): CRC Press/Taylor and Francis Group; 2016. Chapter 19.
   Google Scholar
• Mathias JL, Alvaro PK. Prevalence of sleep disturbances, disorders, and problems following traumatic brain injury: a meta-analysis. Sleep Med. 2012;13:898–905. doi:10.1016/j.sleep.2012.04.006.
   PubMed Web of Science ®Google Scholar
• Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancet Neurol. 2015, May;14(5):506–17. doi:10.1016/S1474-4422(15)00002-2.
   PubMed Web of Science ®Google Scholar
• Roberts A. Brain damage in boxers: a study of prevalence of traumatic encephalopathy among ex-professional boxers. London: Pitman Medical Scientific Publishing Co; 1969.
   Google Scholar
• Omalu B, Bailes J, Hamilton RL, Kamboh MI, Hammers J, Case M, Fitzsimmons R. Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. Neurosurgery. 2011;69:173–83. doi:10.1227/NEU.0b013e318212bc7b.
   PubMed Web of Science ®Google Scholar
• McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136:43–64. doi:10.1093/brain/aws307.
   PubMed Web of Science ®Google Scholar